NASDAQ$CGON
CG Oncology Inc · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
CG Oncology reported Q1 2026 revenue of $1.1M with a net loss of $60.2M as a clinical-stage biotech.
For the quarter ended March 31, 2026, CG Oncology reported total revenues of $1.1 million versus $52 thousand, including license revenue. Net loss was $60.2 million compared with $60.0 million a year ago. The company had $1.08 billion in cash and marketable securities and is developing cretostimogene for bladder cancer.
- Revenue of $1.1M from collaboration and license activity.
- Net loss of $60.2M on R&D spend of $43.7M.
- Cash balance above $1B after equity raises.
- Clinical-stage with no commercial product yet.
- Jefferies ATM program completed during the quarter.
Headline financials
Revenue & EPS history
CG Oncology Inc · Revenue · Quarterly
$1.08M
Forward guidance
Pre-commercial biotech; MD&A focuses on clinical milestones without revenue or EPS guidance.
Tailwinds
- Strong cash runway for pivotal trials.
- Modest revenue from partnerships.
Headwinds
- Substantial ongoing losses until approval.
- Regulatory and clinical trial risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q1 2026
+0.6%
Avg return
Earnings day
+1.8%
Avg return
5 days after
+5.6%
Avg return
30 days after
63%
5 / 8 earnings
Positive
+8.6%
Q3 2025
Best reaction
-7.4%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | +6.9% | -22.5% | |
| Q4 2025 | +4.8% | +9.7% | +15.2% | |
| Q3 2025 | +8.6% | +12.8% | +8.4% | |
| Q2 2025 | +2.1% | +8.8% | +35.8% | |
| Q1 2025 | -3.9% | +1.1% | +5.3% | |
| Q3 2024 | -6.8% | -17.1% | -27.3% | |
| Q2 2024 | +7.0% | +7.9% | +22.5% | |
| Q1 2024 | -7.4% | -15.8% | +7.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro